Astatine-211 based radionuclide therapy: Current clinical trial landscape
Per Albertsson, Tom Bäck, Karin Bergmark, Andreas Hallqvist, Mia Johansson, Emma Aneheim, Sture Lindegren, Chiara Timperanza, Knut T. Smerud, Stig Palm
Abstract
At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.
Topics & Concepts
Clinical trialRadionuclide therapyMedical physicsAstatineMedicineAlpha particleAlpha (finance)RadionuclideNuclear medicineNuclear physicsInternal medicinePhysicsSurgeryPatient satisfactionConstruct validityVoltageQuantum mechanicsRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and ApplicationsLung Cancer Treatments and Mutations